doi:10.3969/j.issn.1004-583X.2023.04.016

Abstract

CLC Number:

R575.5

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2023.04.016

https://huicui.hebmu.edu.cn/EN/Y2023/V38/I4/373

References 31

[1]	Kaya E, Yilmaz Y. Metabolic-associated fatty liver disease (MAFLD): A multi-systemic disease beyond the liver[J]. J Clin Transl Hepatol, 2022, 10(2):329-338. doi: 10.14218/JCTH.2021.00178 pmid: 35528971
[2]	Méndez-Sánchez N, Díaz-Orozco LE. Editorial: International consensus recommendations to replace the terminology of non-Alcoholic fatty liver disease (NAFLD) with metabolic-associated fatty liver disease (MAFLD)[J]. Med Sci Monit, 2021, 27:e933860.
[3]	Xian YX, Weng JP, Xu F. MAFLD vs. NAFLD: Shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy[J]. Chin Med J (Engl), 2020, 134(1):8-19.
[4]	Harrison SA, Bashir MR, Guy CD, et al. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: A multicentre, randomised, double-blind, placebo-controlled, phase 2 trial[J]. Lancet, 2019, 394(10213):2012-2024. doi: S0140-6736(19)32517-6 pmid: 31727409
[5]	Harrison SA, Bashir M, Moussa SE, et al. Effects of resmetirom on noninvasive endpoints in a 36-week phase 2 active treatment extension study in patients with NASH[J]. Hepatol Commun, 2021, 5(4):573-588. doi: 10.1002/hep4.1657 pmid: 33860116
[6]	Younossi ZM, Stepanova M, Taub RA, et al. Hepatic fat reduction due to resmetirom in patients with nonalcoholic steatohepatitis is associated with improvement of quality of life[J]. Clin Gastroenterol Hepatol, 2022, 20(6):1354-1361. doi: 10.1016/j.cgh.2021.07.039 URL
[7]	Caddeo A, Kowalik MA, Serra M, et al. TG68, a novel thyroid hormone receptor-β agonist for the treatment of NAFLD[J]. Int J Mol Sci, 2021, 22(23):13105. doi: 10.3390/ijms222313105 URL
[8]	Caddeo A, Serra M, Sedda F, et al. Potential use of TG68-a novel thyromimetic-for the treatment of non-alcoholic fatty liver (NAFLD)-associated hepatocarcinogenesis[J]. Front Oncol, 2023, 13:1127517. doi: 10.3389/fonc.2023.1127517 URL
[9]	Harrison SA, Neff G, Guy CD, et al. Efficacy and safety of aldafermin, an engineered FGF19 analog, in a randomized, double-blind, placebo-controlled trial of patients with nonalcoholic steatohepatitis[J]. Gastroenterology, 2021, 160(1):219-231. doi: 10.1053/j.gastro.2020.08.004 pmid: 32781086
[10]	Harrison SA, Abdelmalek MF, Neff G, et al. Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): A randomised, double-blind, placebo-controlled, phase 2b trial[J]. Lancet Gastroenterol Hepatol, 2022, 7(7):603-616. doi: 10.1016/S2468-1253(22)00017-6 URL
[11]	Harrison SA, Ruane PJ, Freilich BL, et al. Efruxifermin in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled, phase 2a trial[J]. Nat Med, 2021, 27(7):1262-1271. doi: 10.1038/s41591-021-01425-3 pmid: 34239138
[12]	Harrison SA, Ruane PJ, Freilich B, et al. A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis[J]. JHEP Rep, 2023, 5(1):100563.
[13]	Sanyal A, Charles ED, Neuschwander-Tetri BA, et al. Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: A randomised, double-blind, placebo-controlled, phase 2a trial[J]. Lancet, 2019, 392(10165):2705-2717. doi: S0140-6736(18)31785-9 pmid: 30554783
[14]	Brown EA, Minnich A, Sanyal AJ, et al. Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial[J]. JHEP Rep, 2023, 5(4):100661.
[15]	Alkhouri N, Lawitz E, Noureddin M, et al. GS-0976 (Firsocostat): An investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH)[J]. Expert Opin Investig Drugs, 2020, 29(2):135-141. doi: 10.1080/13543784.2020.1668374 URL
[16]	Calle RA, Amin NB, Carvajal-Gonzalez S, et al. ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: Two parallel, placebo-controlled, randomized phase 2a trials[J]. Nat Med, 2021, 27(10):1836-1848. doi: 10.1038/s41591-021-01489-1 pmid: 34635855
[17]	Syed-Abdul MM, Parks EJ, Gaballah AH, et al. Fatty acid synthase inhibitor TVB-2640 reduces hepatic de novo lipogenesis in males with metabolic abnormalities[J]. Hepatology, 2020, 72(1):103-118. doi: 10.1002/hep.31000 pmid: 31630414
[18]	Loomba R, Mohseni R, Lucas KJ, et al. TVB-2640 (FASN Inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled phase 2a trial[J]. Gastroenterology, 2021, 161(5):1475-1486. doi: 10.1053/j.gastro.2021.07.025 pmid: 34310978
[19]	Fernández-Ramos D, Lopitz-Otsoa F, Delacruz-Villar L, et al. Arachidyl amido cholanoic acid improves liver glucose and lipid homeostasis in nonalcoholic steatohepatitis via AMPK and mTOR regulation[J]. World J Gastroenterol, 2020, 26(34):5101-5117. doi: 10.3748/wjg.v26.i34.5101 URL
[20]	Ratziu V, de Guevara L, Safadi R, et al. Aramchol in patients with nonalcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase 2b trial[J]. Nat Med, 2021, 27(10):1825-1835. doi: 10.1038/s41591-021-01495-3 pmid: 34621052
[21]	Loomba R, Morgan E, Watts L, et al. Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: A multicentre, double-blind, randomised, placebo-controlled phase 2 trial[J]. Lancet Gastroenterol Hepatol, 2020, 5(9):829-838. doi: 10.1016/S2468-1253(20)30186-2 URL
[22]	Akbari R, Behdarvand T, Afarin R, et al. Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis[J]. BMC Pharmacol Toxicol, 2021, 22(1):53. doi: 10.1186/s40360-021-00524-8
[23]	Gawrieh S, Noureddin M, Loo N, et al. Saroglitazar, a PPAR-α/γ Agonist, for treatment of NAFLD: A randomized controlled double-blind phase 2 trial[J]. Hepatology, 2021, 74(4):1809-1824. doi: 10.1002/hep.31843 pmid: 33811367
[24]	Padole P, Arora A, Sharma P, et al. Saroglitazar for nonalcoholic fatty liver disease: A single centre experience in 91 patients[J]. J Clin Exp Hepatol, 2022, 12(2):435-439. doi: 10.1016/j.jceh.2021.06.015 URL
[25]	Younossi ZM, Ratziu V, Loomba R, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: Interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial[J]. Lancet, 2019, 394(10215):2184-2196. doi: S0140-6736(19)33041-7 pmid: 31813633
[26]	Younossi ZM, Stepanova M, Nader F, et al. Obeticholic acid impact on quality of life in patients with nonalcoholic steatohepatitis: REGENERATE 18-month interim analysis[J]. Clin Gastroenterol Hepatol, 2022, 20(9):2050-2058. doi: 10.1016/j.cgh.2021.07.020 URL
[27]	Patel K, Harrison SA, Elkhashab M, et al. Cilofexor, a nonsteroidal FXR agonist, in patients with noncirrhotic NASH: A phase 2 randomized controlled trial[J]. Hepatology, 2020, 72(1):58-71. doi: 10.1002/hep.31205 pmid: 32115759
[28]	Alkhouri N, Herring R, Kabler H, et al. Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial[J]. J Hepatol, 2022, 77(3):607-618. doi: 10.1016/j.jhep.2022.04.003 URL
[29]	Harrison SA, Bashir MR, Lee KJ, et al. A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis[J]. J Hepatol, 2021, 75(1):25-33. doi: 10.1016/j.jhep.2021.01.047 pmid: 33581174
[30]	Friedman SL, Ratziu V, Harrison SA, et al. A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis[J]. Hepatology, 2018, 67(5):1754-1767. doi: 10.1002/hep.29477 pmid: 28833331
[31]	Ratziu V, Sanyal A, Harrison SA, et al. Cenicriviroc treatment for adults with nonalcoholic steatohepatitis and fibrosis: Final analysis of the phase 2b CENTAUR study[J]. Hepatology, 2020, 72(3):892-905. doi: 10.1002/hep.31108 URL

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 31

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	. [J]. Clinical Focus, 2023, 38(10): 935-939.
[2]	. [J]. Clinical Focus, 2023, 38(6): 559-563.
[3]	Cao Yumeng, Zhang Haiyan, Liu Lixin. Correlation between pathological changes and serum ferritin and iron levels in nonalcoholic fatty liver disease: A meta-analysis [J]. Clinical Focus, 2023, 38(3): 197-207.
[4]	. [J]. Clinical Focus, 2022, 37(9): 846-854.
[5]	Zhang Limin, Sun Jun. Predictive value of FIB-4 in patients with metabolic-associated fatty liver disease complicated with colorectal adenomatous polyps [J]. Clinical Focus, 2022, 37(4): 334-338.
[6]	Wen Jie. Correlation analysis between atherogenic index of plasma and nonalcoholic fatty liver disease [J]. Clinical Focus, 2022, 37(1): 35-38.
[7]	Li Guohuan, Xie Xu, Huang Zhixia, Zhang Mingye, Tang Yunyun. Quantitative evaluation of transient elastography and acoustic radiation force pulse imaging for non-alcoholic fatty liver disease [J]. Clinical Focus, 2021, 36(6): 535-539.
[8]	Zhang Ying, Wang Chunsheng. Effects of Jiangzhi Ligan Granules combined with simvastatin on hepatic biochemical indexes, leptin and adiponectin in treatment of NAFLD [J]. Clinical Focus, 2021, 36(1): 58-61.
[9]	Lu Xiaomin;Wang Zhenning;Yang Jun;Cui Zheng. Detection of serum iron in alcoholic and non-alcoholic fatty liver disease [J]. Clinical Focus, 2015, 30(9): 1033-1035.
[10]	WAN Shun-mei;WU Yong-sheng;ZHU Ping;LI Wan-jun;WAN Ping-xin;YANG Wei-jie;PAN Li. Significance of oxygen free radical metabolism in nonalcoholic fatty liver in high-altitude regions [J]. Clinical Focus, 2014, 29(6): 670-671672.
[11]	. [J]. CLINICAL FOCUS, 2014, 29(4): 474-477.
[12]	. [J]. Clinical Focus, 2013, 28(5): 540-542.
[13]	ZHANG Zi-yu;LUO Wen-ming. Relationship of fatty liver detected by B-ultrasound with serum lipid level and hepatic function [J]. Clinical Focus, 2012, 27(23): 2050-2052.
[14]	. [J]. Clinical Focus, 2012, 27(22): 1977-1979.
[15]	. [J]. Clinical Focus, 2012, 27(17): 1512-1513.